Content Marketing’s Data Fail: Information Without Insight?
26 October 2016
A recent conference on content marketing encapsulated what has been a growing problem in efforts to glean insights from today’s swell of healthcare information: An astounding number of statistics were presented with no context, along with infographics with much more focus on the visuals and little picture elements, and no scrutiny on the totality of erroneous and misrepresented data.
Epic Sciences to Contribute to Cancer Moonshot Blood Profiling Atlas
25 October 2016
Epic Sciences in collaboration with other industry, academic, and government partners will contribute to the Blood Profiling Atlas pilot of the Cancer Moonshot Initiative championed by Vice President Biden and the White House. The Blood Profiling Atlas seeks to create an open database of results from liquid biopsy tests to accelerate the development of safe and effective blood profiling diagnostics for patient benefit.
UK aims to cut four years from drug development process
25 October 2016
The government has published its long-awaited Accelerated Access Review, a report that aims to cut up to four years from the process that gets a drug from the lab to use on England’s National Health Service.
The Importance of Stakeholder Research in Rare Disease Drug Development
25 October 2016
The approval of novel orphan drug designations continues to grow, while many existing rare disease therapies are receiving approval for expanded indications. With this increase and broadening class of products, including some that target the same mutation or molecular defect, sponsors face new and significant market access challenges in securing reimbursement.
US and Europe Collaborate on Patient Treatments
24 October 2016
In an Oct. 18, 2016 FDAVoice blog post, Jonathan C. Goldsmith, MD, associate director of FDA’s Rare Diseases Program in the Center for Drug Evaluation and Research’s (CDER) Office of New Drugs, and Sandra Kweder, MD, deputy director of FDA’s Europe office and liaison to the European Medicines Agency (EMA), expressed their excitement over FDA’s collaboration with EMA to advance treatments for rare diseases and engage with patients.
Patients covered by government programs need not apply
24 October 2016
When Mylan NV tried to put out the public outcry over its latest hike in the Epipen price by expanding its patient assistance programs (PAPs), U.S. lawmakers weren't impressed. "PAPs seem like a playbook all [drug] companies are using instead of coming down on the price," Rep. Elijah Cummings (D-Md.) responded last month to Mylan CEO Heather Bresch's testimony before the House Oversight and Government Reform Committee about the Epipen price increases.
Patient assistance programs keep growing and changing to meet demand
21 October 2016
The rise of a complex and lucrative specialty drug market in the U.S. has created not only new opportunities for drugmakers, but also new challenges. With a significant portion of care shifting from in-patient to out-patient settings and insurers tightening the reins on specialty drug coverage, drugmakers have turned to patient assistance programs (PAPs) to help them succeed.
PAPs valuable but increasingly ensnared in drug pricing predicament
21 October 2016
Millions of U.S. consumers hear and read those words every day in direct-to-consumer (DTC) ads from the London-based pharma and similar verbiage from its cohorts. Copay assistance, discounted pricing and free medications for those who qualify are hallmarks of the biopharma industry's ubiquitous patient assistance programs (PAPs), which also encompass services such as insurance reimbursement support, counseling, genetic testing, health care classes and certain devices.
20 October 2016
Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases, today announced the acceptance of the company’s late breaking abstract as an oral presentation at the American Academy for the Study of Liver Diseases (AASLD) Annual Meeting (the Liver Meeting®), being held in Boston, MA from November 11-15, 2016.
Study Demonstrates Potential Method for Treating Congenital Diseases In Utero
20 October 2016
A team of researchers have demonstrated a potential method for treating congenital diseases in utero. In a new study published on Sept. 28, 2016 inNucleic Acids Research, scientists from Rosalind Franklin University of Medicine and Oregon Health & Science University demonstrate the drug delivery of antisense oligonucleotides (ASOs) to amniotic fluid in utero to treat genetic defects in mice.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
The overall mortality rate of the population in Russia decreased by 7% in 2023
28 March 2024
Russia to collaborate with Hungary and Serbia in nuclear medicine
28 March 2024
Researchers propose novel test for pyrogen detection
27 March 2024
Parkinson’s infusion treatment demonstrates advantage over oral delivery
27 March 2024